Alpha Tau Medical Ltd. (DRTS) - What Are Investment Firms Saying About This Stock?

Key Points

• Analysts have a consensus “Hold” rating on Alpha Tau Medical: five of eight covering firms recommend buying, one says hold and two recommend selling. The average 12-month price target is $15.40, with Barclays’ target raised to $30.
• The company reported a quarterly loss of $0.50 per share, missing analysts’ estimate of a $0.14 loss; analysts expect a full-year loss of $1.05 per share.
• Shares opened at $13.72, within a 52-week range of $3.43 to $15.79. CFO Raphi Levy sold 2,871 shares under a pre-arranged trading plan, reducing his stake by 3.09%.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.40.

Several equities analysts have commented on the company. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, October 20th. Barclays boosted their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, September 3rd. Benchmark restated a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Zacks Research downgraded Alpha Tau Medical from a "hold" rating to a "strong sell" rating in a research note on Tuesday, September 1st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a report on Thursday, October 15th.

Alpha Tau Medical Price Performance

Shares of DRTS opened at $13.72 on Monday. Alpha Tau Medical has a 52 week low of $3.43 and a 52 week high of $15.79. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.19 and a beta of 1.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. The stock has a fifty day moving average of $14.13 and a 200-day moving average of $10.75.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). As a group, sell-side analysts anticipate that Alpha Tau Medical will post -1.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the business's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the sale, the chief financial officer directly owned 90,180 shares of the company's stock, valued at $1,352,700. The trade was a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alpha Tau Medical

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in Alpha Tau Medical in the first quarter valued at $286,000. Principal Financial Group Inc. bought a new position in Alpha Tau Medical during the 1st quarter worth $132,000. Finally, Everhart Financial Group Inc. bought a new position in Alpha Tau Medical during the 2nd quarter worth $126,000. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing targeted radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver highly localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses tiny radioactive sources, including radium-224, that are placed in or near a tumor. The sources generate short-range alpha-emitting atoms that diffuse through the tumor and damage cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.